Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)

Summary

This study consists of a 4-week screening period, a 24-week treatment period for all participants, followed by a 28-week treatment period extension (to 52 weeks in total) for a subset of at least 60 and up to 80 participants, and a 2-week post-treatment follow-up period.

Timeline

Start

2018-07-13

Primary completion

2020-03-17

Completion

2020-03-17

Drugs

Indications